Endpoints quoted in trial document(s) (ClinicalTrials.gov, FDA/EMA document, manufacturer's website, published design paper)a	Study results posted in trial register [Yes/No]	Publications specified in trial register	Endpoints quoted in publication(s)b,c	Endpoints quoted in abstract of publication(s)b,c
Barczynski 2012	Source: NCT01408368 Primary outcome measure(s): long term control of Graves' disease (time frame: up to 60 months postoperatively), recurrence rate of hyperthyroidism and change in Graves' ophthalmopathy	No	Yes	Primary outcome measure(s): prevalence of recurrent hyperthyroidism during follow‐up and changes in Graves’ ophthalmopathy	Primary outcome measure(s): prevalence of recurrent hyperthyroidism and changes in Graves’ ophthalmopathy
	Secondary outcome measure(s): morbidity rate (time frame: up to 12 months postoperatively), RLN injury and hypoparathyroidism			Secondary outcome measure(s): postoperative hypoparathyroidism and recurrent RLN injury	Secondary outcome measure(s): postoperative transient and permanent paresis of the RLN, postoperative hypocalcaemia and hypoparathyroidism
	Other outcome measure(s): ‐			Other outcome measure(s): serum free triiodothyronine, free thyroxine and thyroid‐stimulating hormone, serum thyrotropin binding inhibitory immunoglobulin (TBII) levels, ophthalmological assessment, clinical activity score to evaluate the activity of the ophthalmopathy, high‐resolution Doppler ultrasonography of the neck, duration of operation, parathyroid autotransplantation, parathyroid glands identified by histology in thyroid specimens, incidental papillary thyroid cancer, diameter of thyroid cancer	Other outcome measure(s):
Chi 2005	N/T			Primary outcome measure(s): ‐	Primary outcome measure(s): ‐
				Secondary outcome measure(s): ‐	Secondary outcome measure(s): ‐
				Other outcome measure(s): operative time, triiodothyronine (T3), thyroxine (T4), thyrotropin (TSH), and antimicrosomal antibodies, postoperative serum calcium, permanent hypoparathyroidism, complications (postoperative mortality, RLN palsy, wound haematoma or bleeding after thyroidectomy, need of calcium medication), recurrent hyperthyroidism, hypothyroidism, incidental carcinoma	Other outcome measure(s): operative time, recurrent hyperthyroidism, hypothyroidism, postoperative complications
Witte 2000	N/T			Primary outcome measure(s): ‐	Primary outcome measure(s): ‐
				Secondary outcome measure(s): ‐	Secondary outcome measure(s): ‐
				Other outcome measure(s): thyroid‐stimulating hormone receptor antibodies (TSH‐RAb), postoperative total remnant size measured by ultrasonography, clinical courses of Graves’ ophthalmopathy using the modified scale system of the American Thyroid Association (ATA), early postoperative complications (RLN palsy, hypothyroidism, wound infection) until discharge from hospital, long‐term results of changes in endocrine orbitopathy, serum calcium levels, vocal cord motility, and TSH‐RAb titers were measured between 18 and 58 months after thyroid operation	Other outcome measure(s): postoperative Graves’ ophthalmopathy changes, postoperative TSH‐RAb titers, postoperative complication rates
Jarhult 2005	N/T			Primary outcome measure(s): ‐	Primary outcome measure(s): ‐
				Secondary outcome measure(s): ‐	Secondary outcome measure(s): ‐
				Other outcome measure(s): evaluation of ophthalmopathy, patients overall opinion about the actual eye problems was expressed on a visual analogue scale, thyroid remnant, operating time, reoperation due to bleeding, hospital stay, permanent vocal cord palsy, permanent hypothyroidism, TSH, free triiodothyronine (T3) and free thyroxine (T4), thyrotropin receptor antibodies (TRAB) titre, calcium	Other outcome measure(s): development of ophthalmopathy, thyrotropin (TSH)‐receptor antibody levels, surgical complication rate (permanent RLN paresis and permanent hypoparathyroidism)
Muller 2001	N/T			Primary outcome measure(s): ‐	Primary outcome measure(s): ‐
				Secondary outcome measure(s): ‐	Secondary outcome measure(s): ‐
				Other outcome measure(s): recurrent hyperthyroidism, regression of Graves' ophthalmopathy, all‐cause mortality, adverse events	Other outcome measure(s): mortality, recurrent laryngeal nerve palsy, hypocalcaemia, secondary haemorrhage, wound infections, recurrence rate
‐ denotes not reported aTrial document(s) refers to all available information from published design papers and sources other than regular publications (e.g. FDA/EMA documents, manufacturer's websites, trial registers) bPublication(s) refers to trial information published in scientific journals (primary reference, duplicate publications, companion documents or multiple reports of a primary study) cOther outcome measures refer to all outcomes not specified as primary or secondary outcome measures EMA: European Medicines Agency; FDA: Food and Drug Administration (US); N/T: no trial document available; RLN: recurrent laryngeal nerve